September 09, 2024

Discontinuation of CML Therapy: Which Patients Are Ideal Candidates?

“Stopping tyrosine kinase inhibitor therapy is something we get a lot of questions about from both patients and their referring physicians,” said Amelia A. Langston, MD. Although their efficacy is ind...

September 09, 2024

Discontinuation of CML Therapy: Which Patients Are Ideal Candidates?

“Stopping tyrosine kinase inhibitor therapy is something we get a lot of questions about from both patients and their referring physicians,” said Amelia A. Langston, MD. Although their efficacy is ind...

September 09, 2024

What Is the Better Target for Bispecific Antibodies in Multiple Myeloma: BCMA or GPRC5D?

For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor class C gr...

August 29, 2024

What Is the Better Target for Bispecific Antibodies in Multiple Myeloma: BCMA or GPRC5D?

For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor class C gr...

August 26, 2024

An Integrated Approach to Treating Cancer and Cardiovascular Disease: When Oncologists and Cardiologists Collaborate

At the 2024 Debates and Didactics in Hematology and Oncology Conference, sponsored by Emory’s Winship Cancer Institute, cardiologist-by-training Anant Mandawat, MD, FACC, briefly reviewed how the emer...

August 13, 2024

Discontinuation of CML Therapy: Which Patients Are Ideal Candidates?

“Stopping tyrosine kinase inhibitor therapy is something we get a lot of questions about from both patients and their referring physicians,” said Amelia A. Langston, MD. Although their efficacy is ind...